Zai Lab (NASDAQ:ZLAB) Director William Lis Sells 7,040 Shares

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Director William Lis sold 7,040 shares of the company’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $18.09, for a total transaction of $127,353.60. Following the completion of the sale, the director owned 50,437 shares of the company’s stock, valued at $912,405.33. This represents a 12.25% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Zai Lab Trading Down 0.6%

Zai Lab stock traded down $0.12 during mid-day trading on Wednesday, hitting $18.37. 1,131,581 shares of the company’s stock were exchanged, compared to its average volume of 812,523. Zai Lab Limited Unsponsored ADR has a 1-year low of $15.96 and a 1-year high of $41.20. The stock has a 50 day moving average of $19.63 and a two-hundred day moving average of $18.98. The stock has a market cap of $2.08 billion, a P/E ratio of -11.34 and a beta of 0.78.

Zai Lab (NASDAQ:ZLAB) last announced its quarterly earnings results on Wednesday, April 1st. The company reported ($0.50) earnings per share for the quarter. The company had revenue of $99.61 million during the quarter. Zai Lab had a negative return on equity of 24.32% and a negative net margin of 39.29%. As a group, research analysts predict that Zai Lab Limited Unsponsored ADR will post -2.23 EPS for the current fiscal year.

Institutional Trading of Zai Lab

A hedge fund recently raised its stake in Zai Lab stock. SG Americas Securities LLC raised its holdings in shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 6.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 10,396 shares of the company’s stock after buying an additional 642 shares during the quarter. SG Americas Securities LLC’s holdings in Zai Lab were worth $183,000 as of its most recent SEC filing. 41.65% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on ZLAB shares. Wall Street Zen cut Zai Lab from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. JPMorgan Chase & Co. dropped their price target on shares of Zai Lab from $39.00 to $32.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 18th. Citigroup reduced their price objective on shares of Zai Lab from $47.00 to $44.00 and set a “buy” rating for the company in a research note on Friday, May 8th. Cantor Fitzgerald decreased their price objective on shares of Zai Lab from $55.00 to $37.00 and set an “overweight” rating for the company in a report on Friday, February 27th. Finally, Weiss Ratings lowered shares of Zai Lab from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 4th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Zai Lab has a consensus rating of “Moderate Buy” and an average price target of $45.83.

About Zai Lab

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.